AlloVir Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-190.42	-168.71	-171.96	-69.78	-23.84	-8.16
Depreciation & Amortization	8.29	2.57	1.12	0.07	0.02	0
Share-Based Compensation	40.78	41.32	43.98	9.43	2.89	0.97
Other Operating Activities	16.9	-17.22	20.55	-0.53	0.78	3.41
Operating Cash Flow	-124.45	-142.05	-106.32	-60.81	-20.16	1.94
Capital Expenditures	0	0	-0.03	-0.24	-0.34	0
Change in Investments	37.99	-80.48	186.01	-169.26	-64.31	0
Investing Cash Flow	37.99	-80.48	185.98	-169.5	-64.64	0
Share Issuance / Repurchase	70.5	126.96	0.23	291.98	0	0
Other Financing Activities	-	-	-	-	120.92	22.87
Financing Cash Flow	70.5	126.96	0.23	291.98	120.92	22.87
Exchange Rate Effect	0	0	-0.04	-0.09	0	0
Net Cash Flow	-15.97	-95.57	79.85	61.58	36.12	24.82
Free Cash Flow	-124.45	-142.05	-106.35	-61.05	-20.49	1.94
Free Cash Flow Margin	-	-	-	-	-12420.61%	171.19%
Free Cash Flow Per Share	-1.20	-1.85	-1.69	-2.27	-15.94	6.38

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).